Filtered By:
Condition: Heart Attack
Procedure: Heart Transplant
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 40 results found since Jan 2013.

Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study
Conclusions: In a cohort of participants with CKD, low serum bicarbonate level was an independent risk factor for kidney disease progression, particularly for participants with preserved kidney function. The risk of heart failure was higher at the upper extreme of serum bicarbonate levels. There was no association between serum bicarbonate level and all-cause mortality or atherosclerotic events.
Source: American Journal of Kidney Diseases - March 13, 2013 Category: Urology & Nephrology Authors: Mirela Dobre, Wei Yang, Jing Chen, Paul Drawz, L. Lee Hamm, Edward Horwitz, Thomas Hostetter, Bernard Jaar, Claudia M. Lora, Lisa Nessel, Akinlolu Ojo, Julia Scialla, Susan Steigerwalt, Valerie Teal, Myles Wolf, Mahboob Rahman, CRIC Investigators Tags: Pathogenesis and Treatment of Kidney Disease Source Type: research

Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease
Conclusions Our study confirms that FGF23 is an important cardiovascular risk factor. Two measurements of FGF23 have no added value over a single value to predict the cardiovascular outcome. This study demonstrates that, under routine clinical practice, the variability of FGF23 in 2 years' time is small. Concomitantly, this study showed no benefit of consecutive FGF23 testing for estimating the risk of a clinical event in an individual patient.
Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Bouma-de Krijger, A., Bots, M. L., Vervloet, M. G., Blankestijn, P. J., ter Wee, P. W., van Zuilen, A. D., Wetzels, J. F. Tags: Chronic Kidney Disease Source Type: research

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Conclusions Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114)
Source: Nephrology Dialysis Transplantation - February 28, 2014 Category: Urology & Nephrology Authors: Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., Tegegne, G. G. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research

Preoperative atrial fibrillation and outcome in patients undergoing on-pump or off-pump coronary bypass surgery: lessons learned from the GOPCABE trial
CONCLUSIONS AF at admission is a significant risk factor for elderly patients undergoing coronary bypass grafting. However, this risk is not altered by performing bypass grafting off pump.
Source: Interactive CardioVascular and Thoracic Surgery - December 18, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Boning, A., Diegeler, A., Hilker, M., Zacher, M., Reents, W., Faerber, G., Doenst, T., for the GOPCABE investigators Tags: Molecular biology, Myocardial infarction, Myocardial protection, Transplantation - heart Adult Cardiac Source Type: research

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
Background Blood pressure (BP) control and reduction of urinary protein excretion using agents that block the renin–angiotensin aldosterone system are the mainstay of therapy for chronic kidney disease (CKD). Research has confirmed the benefits in mild CKD, but data on angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use in advanced CKD are lacking. In the STOP-ACEi trial, we aim to confirm preliminary findings which suggest that withdrawal of ACEi/ARB treatment can stabilize or even improve renal function in patients with advanced progressive CKD. Methods The STOP-ACEi trial (tri...
Source: Nephrology Dialysis Transplantation - January 25, 2016 Category: Urology & Nephrology Authors: Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., El Nahas, M. Tags: Chronic Kidney Disease Source Type: research

Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure)
Conclusion In Asian type 2 diabetic patients with chronic kidney disease and heavy proteinuria, reduction of SBP ≤ 130 mmHg was associated with greater renoprotection than cardioprotection. However, our results emphasize the need to individualize BP targets in type 2 diabetes.
Source: Nephrology Dialysis Transplantation - February 22, 2016 Category: Urology & Nephrology Authors: Imai, E., Ito, S., Haneda, M., Harada, A., Kobayashi, F., Yamasaki, T., Makino, H., Chan, J. C. N. Tags: Chronic Kidney Disease Source Type: research

Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.
CONCLUSIONS: Compared with thiazide diuretics, calcium channel blockers were associated with a lower risk of significant kidney events and a similar risk of cardiovascular events. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_03_23_CJASNPodcast_18_5_S.mp3. PMID: 29572286 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 23, 2018 Category: Urology & Nephrology Authors: Schroeder EB, Chonchol M, Shetterly SM, Powers JD, Adams JL, Schmittdiel JA, Nichols GA, O'Connor PJ, Steiner JF Tags: Clin J Am Soc Nephrol Source Type: research

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
Source: American Heart Journal - September 6, 2018 Category: Cardiology Source Type: research

Sternal wound complications in patients undergoing orthotopic heart transplantation
ConclusionSternal wound infections impart a significant burden on patients with OHT. Causative organisms are predominantly virulent gram ‐negative bacteria. Therefore, a high index of suspicion must be maintained for early detection and treatment.
Source: Journal of Cardiac Surgery - February 25, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Tyler J. Wallen, Andreas Habertheuer, Jean P. Gottret, Matthew Kramer, Zara Abbas, Mary Siki, Reilly Hobbs, Charlie Vasquez, Maria Molina, Suhail Kanchwala, David Low, Michael Acker, Prashanth Vallabhajosyula Tags: ORIGINAL ARTICLE Source Type: research

Long-Term Single Centre Outcomes of Patients with Chronic Renal Dialysis Undergoing Cardiac Surgery
CONCLUSIONSCardiac surgery in DD-CRF patients is associated with high morbidity and mortality. Interestingly, overall mortality was mainly none cardiac-related, where elderly patients or those presented with CHF had the worst life expectancy. However, subsequent kidney transplantation positively impact long-term survival in such patients.
Source: The Annals of Thoracic Surgery - September 27, 2019 Category: Cardiovascular & Thoracic Surgery Source Type: research

Long-Term Single Centre Outcomes of Patients with Chronic Renal Dialysis Undergoing Cardiac Surgery.
CONCLUSIONS: Cardiac surgery in DD-CRF patients is associated with high morbidity and mortality. Interestingly, overall mortality was mainly none cardiac-related, where elderly patients or those presented with CHF had the worst life expectancy. However, subsequent kidney transplantation positively impact long-term survival in such patients. PMID: 31563486 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - September 25, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Mourad F, Cleve N, Nowak J, Wendt D, Sander A, Demircioglu E, El Gabry M, Jakob H, Shehada SE Tags: Ann Thorac Surg Source Type: research

Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study
ConclusionsHigher MPO level was associated with increased risk for CKD progression, but not with CVD and death in patients with CKD from CRIC. Whether therapies aimed at reducing MPO activity can result in improved clinical outcomes is yet to be determined.
Source: American Journal of Kidney Diseases - December 20, 2019 Category: Urology & Nephrology Source Type: research

Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data
ConclusionCREDEM-DKD is an important new tool in the evaluation of treatment interventions in the DKD population.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - September 14, 2020 Category: Endocrinology Source Type: research

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type  2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
ConclusionModel results suggest that adding canagliflozin 100  mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - December 2, 2020 Category: Endocrinology Source Type: research

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
ConclusionThe significant adverse renal and cardiovascular outcomes observed, particularly in the DAPA-CKD-like cohort, represent a substantial burden resulting in increased mortality, HCRU and costs, demonstrating the need for additional treatment options.
Source: Advances in Therapy - January 20, 2021 Category: Drugs & Pharmacology Source Type: research